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ABSTRACT
Objective: To identify, in caregivers of patients with Alzheimer’s disease (AD) dementia, factors associated with
subjective (personal, physical, emotional, and social) and objective (informal caregiver time and costs)
caregiver burden.
Design: Prospective longitudinal European observational study: post-hoc analysis.
Setting: Clinic.
Participants: Community-dwelling patients in France and Germany aged ≥ 55 years (n= 969) with probable
AD and their informal caregivers.
Measurements: Mini-Mental State Examination (MMSE), Alzheimer’s Disease Cooperative Study—Activities
of Daily Living (ADCS-ADL), 12-item Neuropsychiatric Inventory (NPI-12), Zarit Burden Interview (ZBI),
informal caregiver basic and instrumental ADL hours (Resource Utilization in Dementia instrument), and
informal caregiver costs. Mixed-effect models of repeated measures (MMRM) were run, including baseline
and time-dependent covariates (change from baseline [CFB] to 18 months in MMSE, ADCS-ADL, and NPI-
12 scores) associated with CFB in ZBI score/informal caregiver time over 36 months (analyzed using linear
regression models) and informal caregiver costs over 36 months (analyzed using generalized linear models).
Results: Greater decline in patient function (ADCS-ADL) over 18 months was associated with increased
subjective caregiver burden (ZBI), hours, and costs over 36 months. Increased behavioral problems (NPI-12)
over 18months also negatively impacted ZBI. Cognitive decline (MMSE) over 18months did not affect change
in caregiver burden.
Conclusions: Long-term informal caregiver burden was driven by worsening functional abilities and behavioral
symptoms but not cognitive decline, over 18 months in community-dwelling patients with AD dementia.
Identifying the drivers of caregiver burden could highlight areas in which interventions may benefit both
caregivers and patients.
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Introduction
Many individuals with Alzheimer’s disease (AD) are
cared for at home by family members or friends
(Alzheimer’s Association, 2017; Wimo et al., 2017).
Such informal caregiving makes a substantial con-
tribution to the overall care of patients with AD
dementia (ADD), helping to keep individuals out of
long-term institutional care for as long as possible.
However, it can have numerous negative financial,
social, health, and quality-of-life consequences for
the caregiver (“caregiver burden”), which may
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increase as the disease progresses (Beinart et al.,
2012; Bergvall et al., 2011; Conde-Sala et al., 2014;
Fisher et al., 2011). As a multidimensional con-
struct, the caregiver burden is generally considered
to comprise both subjective (e.g. personal, physical,
emotional, and social) and more objective (e.g.
informal caregiver time and costs) aspects of caring
(Park et al., 2015).
Costs associated with informal caregiver time
form a major component of the societal costs of
AD but can be challenging to determine (Darbà
et al., 2015; Gervès et al., 2014; Shearer et al., 2012;
Wimo et al., 2013).
The most widely used measure of perceived
caregiver burden, the self-rated Zarit Burden Inter-
view (ZBI; Zarit et al., 1980), focuses on subjective
aspects of this burden. Cross-sectional studies have
identified numerous disease-related factors (e.g. the
patient’s cognitive status, functional impairment,
and behavioral symptoms), as well as various care-
giver characteristics (e.g. their relationship to the
patient andwhether living with the patient or not), as
being associated with the subjective caregiver bur-
den (Beinart et al., 2012; Bergvall et al., 2011;
Brodaty et al., 2014; Conde-Sala et al., 2014; Park
et al., 2015). More objective but equally important
burden indicators, such as caregiver time and costs,
and how they change with the progression of ADD
severity, have received less attention (Bergvall et al.,
2011; Fisher et al., 2011; Koca et al., 2017; Wolfs
et al., 2012). Identifying drivers of the caregiver
burden at different stages of AD could highlight
areas in which interventions may benefit both care-
givers and patients.
Few longitudinal studies have investigated the
impact on informal caregiver burden of AD progres-
sion from the early stages of mild cognitive
impairment or mild ADD. Existing studies report
an increase in subjective caregiver burden (worsening
ZBI score) as being associated more with worsening
patient functional status and behavioral problems
than with cognitive decline (Brodaty et al., 2014;
Conde-Sala et al., 2014; Jones et al., 2017). Of these
studies, only Jones et al. (2017), an 18-month post-hoc
analysis of the GERAS study, a prospective longitu-
dinal European observational study designed to
assess costs and resource use associated with ADD,
investigated the impact of AD progression on objec-
tive aspects of the caregiver burden. In this study,
progression to amore severe state was associatedwith
increases in caregiver time and total societal costs
(including informal care costs).
To increase understanding of the wider impact of
caring for a patient with ADD, a post-hoc exploratory
analysis of data from the GERAS study was con-
ducted to identify patient and caregiver factors
associated with both subjective and objective
caregiver outcomes. Outcomes investigated over
36 months included the caregiver burden (assessed
using the ZBI) and caregiver informal care time
and costs.
Methods
Study design and cohort
GERAS was an 18-month prospective observational
study of costs and resource use in community-living
patients with ADD and their caregivers conducted
in France, Germany, and the U.K.; the study was
extended to 36 months in France and Germany.
Study design and baseline data for all three countries
have been described previously (Wimo et al., 2013).
This paper reports a post-hoc analysis of 36-month
outcomes in the French and German cohorts.
In brief, the study enrolled community-dwelling
patients aged ≥ 55 years with a diagnosis of probable
AD (defined according to criteria inMcKhann et al.,
1984) and a Mini-Mental State Examination
(MMSE) score (Folstein et al., 1975) of ≤ 26 who
presented during the normal course of care. Exclu-
sion criteria included a history, clinical signs, or
imaging evidence of stroke or transient ischemic
attack; a history of Parkinson’s disease prior to/
coincidental with the onset of AD; and probable
Lewy-body disease.
All patients had an informal caregiver (a person
taking responsibility for most day-to-day decisions
and the provision of home care for the patient) who
was willing to participate in the study and undertake
responsibility for the patient for ≥ 6 months of
the year.
Patients were stratified according to baseline dis-
ease severity usingMMSE criteria (National Institute
for Health and Care Excellence, 2011): MMSE
21− 26 points—mild AD severity; MMSE 15− 20
points—moderate AD severity;MMSE<15 points—
moderately severe/severe AD severity. Recruitment
was designed to achieve equal numbers of patients in
each AD severity group within each country (Wimo
et al., 2013).Throughout the study, patients could be
prescribed AD treatment as per usual care.
The study was approved by local Ethical Review
Boards according to individual country regulations.
Written informed consent was obtained from both
patient (or legal representative, as determined at
study site) and caregiver prior to study enrollment,
which occurred betweenOctober 2010 and Septem-
ber 2011.
Assessments
Data were collected at baseline and during routine
care visits at 6-month intervals up to 36 months in
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France andGermany. Information collected at base-
line for patients and caregivers included sociodemo-
graphic data, comorbidities, and medications.
Additional data collected and used in our analyses
are listed in the Supplementary Material.
Caregiver informal care costs
Caregiver informal care costs (assessed every six
months) were calculated based on an opportunity
cost approach, taking into account productivity loss
for working caregivers and lost leisure time for
nonworking caregivers. Caregiver time (calculated
as the number of hours spent assisting the patient
with basic and instrumental activities of daily living
[ADL] [caregiver basic ADL hours and caregiver
instrumental ADL hours]) was capped at 24 hours/
day. The unit cost of caregiver time for working
caregivers was the value of lost production time
based on the national average wage per country;
for nonworking caregivers, it was the value of lost
leisure time, based on 35% of the national average
wage per country population (see Wimo et al.,
2013). All costs were calculated in € (2010 values).
For patients with missing data, costs were imputed
based on the reason the data were missing. For
patients institutionalized during the study, mean
monthly costs from the last visit were used for the
period up to institutionalization, followed by zero
costs from institutionalization to 36 months. For
patients who died, last observation carried forward
was used, with costs from the last known visit
extrapolated to date of death (no costs were com-
puted thereafter) (Belger et al., 2016). For patients
who discontinued the study for other reasons, mul-
tiple imputation (MI) regression (Rubin, 1987),
stratified byMMSE group and using factors selected
from those identified by Dodel et al. (2015), was
performed on missing costs.
Statistical analysis
The post-hoc analysis reported was exploratory only.
Demographics and baseline characteristics were
summarized using descriptive statistics, based on
nonmissing observations.
The primary analysis aimed to identify patient
and caregiver covariates associated with change
from baseline (CFB) over 36 months for the out-
come measured ZBI total score, caregiver basic
ADL hours, and caregiver instrumental ADL hours.
The analysis also identified patient and caregiver
covariates associated with informal caregiver costs
over 36 months.
The choice of baseline patient and caregiver
variables to include in the 36 month models were
those covariates significantly associated with the
outcomes of interest over 18 months. These were
identified by running 100 18-month models using
forward and backward selection; 67% of subjects
were selected at random for inclusion and variables
identified in each model summarized. Inclusion/
exclusion of individual variables was based on a
significance level of 0.05; variables selected
in ≥ 75 iterations were included in the 36-month
models.
A mixed-effects model of repeated measures
(MMRM) was used in all analyses; a maximum of
six repeated measured data points for each patient
were included in the MMRM. The analysis of CFB
outcomes used linear regression models; analysis of
caregiver costs used generalized linear models with a
gamma distribution and a log-link function. The
MMRM models included as main effects patient
and caregiver baseline covariates found to be signif-
icantly associated with the outcomes of interest
(CFB in ZBI, caregiver basic ADL hours and care-
giver instrumental ADL hours, and caregiver costs)
over 18 months; change in score from baseline to 18
months for four time-dependent patient covariates
(MMSE, Alzheimer’s Disease Cooperative Study—
Activities of Daily Living [ADCS-ADL; Galasko
et al., 2005] [basic and instrumental] and 12-item
Neuropsychiatric Inventory [NPI-12; Cummings,
1997); and baseline scores for these time-dependent
covariates.
Mean changes over time are presented as least
squares means (± 95% confidence intervals) taken
from the MMRM analysis. Sensitivity analyses were
performed for ZBI with missing outcomes imputed
using MI (Markov chain Monte Carlo method). As
the method used to calculate cost data resulted in no
missing data, no similar sensitivity analyses were
required for informal care costs.
All data were analyzed using SAS software,
version 9.2 (SAS Institute, Cary, NC, USA).
Results
A total of 969 patients and their informal caregivers
from the French (n= 419) and German (n= 550)
GERAS cohorts were included. Caregivers were
mostly female (65%), the spouse of the patient
(65%), and living with the patient (75%) (Table 1);
64% of caregivers were spouses who lived with the
patient. Although caregivers spent over 200 hours/
month on care, the overall caregiver burden, as
assessed by the ZBI, was relatively low (Table 1).
Differences between patients and caregivers in the
two countries were apparent. For example, French
patients were older, on average, than German
patients, and a higher proportion were female.
Additionally, caregiver time at baseline was notably
higher in Germany than in France.
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At the 36-month follow-up, 572 (59%) patients
had discontinued the study. Main reasons for dis-
continuation included institutionalization (n= 213
[37%]), death (n= 112 [20%]), and loss to follow-
up (n= 247 [43%]).
Caregiver burden (ZBI score)
Mean ZBI total scores increased from baseline
(indicative of greater burden) in both France and
Germany over the 36 months of the GERAS study
(Figure 1).
Primary analysis (Figure 2A) showed that a
greater increase in caregiver burden over 36 months
was most strongly associated with a worsening in
patient functional ability (lower ADCS-ADL instru-
mental score) and an increase in patient behavioral
problems (higher NPI-12 total score) over 18
months. Additionally, a greater increase in caregiver
burden was observed with the patient having more
years of education and a greater number of comor-
bidities. A lower increase in caregiver burden over
36 months was seen when the patient had a greater
Table 1. Baseline characteristics of patients and caregivers
FRANCE (N = 419) GERMANY (N = 550) TOTAL (N = 969)
...................................................................................................................................................................................................................................................................................................................................
Patients
Age, years 79.4 (6.81) 75.2 (7.55) 77.0 (7.53)
Gender (n, % female) 261 (62.3) 273 (49.6) 534 (55.1)
Education, years 9.1 (3.36) 10.6 (2.96) 10.0 (3.22)
Time since AD diagnosis, years 2.5 (2.41) 2.0 (2.14) 2.2 (2.27)
With comorbidities (n, %) 347 (82.8) 412 (74.9) 759 (78.3)
Number of comorbidities 1.8 (1.27) 1.4 (1.19) 1.6 (1.24)
AD dementia severity
Mild (n, %) 138 (32.9) 228 (41.5) 366 (37.8)
Moderate (n, %) 136 (32.5) 156 (28.4) 292 (30.1)
Moderately severe/severe (n, %) 145 (34.6) 166 (30.2) 311 (32.1)
MMSE total score 17.2 (5.73) 17.7 (6.72) 17.5 (6.31)
ADCS-ADL total score 47.4 (18.16) 45.5 (21.92) 46.4 (20.39)
ADCS-ADL basic score 17.6 (4.92) 16.9 (5.65) 17.2 (5.36)
ADCS-ADL instrumental score 29.7 (14.20) 28.5 (17.08) 29.0 (15.90)
NPI-12 total score 14.3 (15.02) 15.4 (16.73) 14.9 (16.02)
Caregiversa
Age, years 67.9 (12.39) 65.9 (11.78) 66.8 (12.08)
Gender (n, % female) 261 (62.4) 372 (67.8) 633 (65.5)
Relationship to patient (n, %)
Spouse 258 (61.7) 371 (67.6) 629 (65.0)
Child 137 (32.8) 132 (24.0) 269 (27.8)
Other 23 (5.5) 46 (8.4) 69 (7.1)
Living with patient (n, %) 308 (73.7) 420 (76.5) 728 (75.3)
Sole caregiver (n, %) 212 (50.7) 352 (64.1) 564 (58.3)
Not married (n, %)b 64 (15.3) 56 (10.2) 120 (12.4)
Working for pay (n, %) 90 (21.5) 157 (28.6) 247 (25.5)
Caregiver basic ADCS-ADL hoursc 25.28 (51.16) 53.15 (99.35) 41.10 (83.19)
Caregiver instrumental ADCS-ADL hoursc 64.02 (73.45) 68.62 (83.54) 66.63 (79.33)
Caregiver supervision hoursc 104.86 (164.26) 122.04 (221.48) 114.61 (198.87)
Overall caregiver hoursc 186.73 (211.29) 209.35 (251.36) 199.57 (235.03)
ZBI total score 30.5 (15.76) 27.5 (14.82) 28.8 (15.30)
ADCS-ADL=Alzheimer’s Disease Cooperative Study—Activities of Daily Living;MMSE=Mini-Mental State Examination; NPI-12= 12-
item Neuropsychiatric Inventory; ZBI=Zarit Burden Interview.
All variables are reported as mean (SD) for nonmissing observations unless otherwise indicated.
All baseline variables listed were considered in the 18-month models; those found to be significantly associated with the outcome of interest
were included in the 36-month models.
aBaseline data missing for two caregivers.
bDivorced/separated, never married, and widowed (includes all caregivers not just spouses/partners).
cPer month.
MMSE 21-26 points—mild AD severity; MMSE 15− 20 points—moderate AD severity; MMSE <15 points—moderately severe/severe AD
severity. MMSE: total score 0–30 (higher score= better cognitive function); NPI-12: total score 0–144 (higher score=more severe
problems); ADCS-ADL: total score 0–78 (basic ADLs: range 0− 22; instrumental ADLs: range 0− 56) (higher scores= lower functional
impairment [i.e. better functioning]); ZBI: total score 0–88 (higher score= greater burden).
270 C. Reed et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1041610219000425
Downloaded from https://www.cambridge.org/core. IP address: 93.176.129.59, on 19 Feb 2021 at 08:28:39, subject to the Cambridge Core terms of use, available at
number of caregivers and the participants lived in
Germany.
In sensitivity analyses, the MI model using time-
dependent variables replicated the findings of
the primary analysis using MMRM (data not
shown).
Caregiver basic ADL hours
Mean caregiver basic ADL hours increased
from baseline in both France and Germany over
the 36months of theGERAS study but were numer-
ically lower, overall, in France than in Germany
(Figure 3A).
In the primary analysis (Figure 2B), a greater
increase in caregiver basic ADL hours over 36
months was associated with a worsening in patient
functioning (lower ADCS-ADL basic score) over 18
months, the caregiver living with the patient, and the
participants living in Germany. Lower patient func-
tioning at baseline (lower ADCS-ADL basic score)
was associated with the greatest increase in caregiver
basic ADL hours over 36 months.
Caregiver instrumental ADL hours
Mean caregiver instrumental ADL hours increased
from baseline in both France and Germany over the
36 months of the GERAS study but were again
numerically lower, overall, in France than in
Germany (Figure 3B).
In the primary analysis, including time-
dependent factors (Figure 2C), a greater increase
in caregiver instrumental ADL hours over 36
months was associated with a worsening in patient
functioning (lower ADCS-ADL instrumental score)
over 18 months. Additionally, a greater increase in
caregiver instrumental ADL hours was observed
when caregivers (including adult-child and spou-
sal/partner caregivers) were not married or were
living with the patient and when the participants
lived in Germany. Lower baseline functioning
(lower ADCS-ADL basic and instrumental scores)
was associated with a greater increase in caregiver
instrumental ADL hours over 36 months.
Caregiver informal care costs
Mean caregiver informal care costs increased from
baseline in Germany over the 36 months of the
GERAS study. In contrast, in France, costs rose
slowly over the first 24 months of the study, return-
ing to original levels during the final 12 months.
Overall, costs were lower in France than inGermany
at all timepoints (Figure 3C).
Primary analysis (Figure 2D) showed that higher
informal care costs over 36 months were associ-
ated with a worsening in patient function (lower
ADCS-ADL instrumental score) over 18 months,
the caregiver (adult-child or spousal/partner) being
unmarried, the caregiver living with the patient, the
caregiver working for pay, and the participants living
in Germany. Lower baseline functioning (lower
ADCS-ADL instrumental score) was associated
with higher 36-month informal care costs.
Discussion
This study provides evidence that a decline in func-
tion, but not cognition, over a period of 18 months
in community-dwelling patients with ADD impacts
key caregiver outcomes over 36 months. In the
context of a correlation between decline in function
and decline in cognition, these analyses assessed
which factors have the largest influence on caregiver
outcomes, and with both function and cognition in
the analyses, our results indicate that after account-
ing for function then decline in cognition does not
Figure 1. Least squares (LS) mean change from baseline (±95% confidence interval) over 36months in caregiver burden (Zarit Burden Index
[ZBI] total score).
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add a statistically significant change in the care-
givers’ outcomes.
Findings of an association between a decline in
functional ability and an increase in subjective
caregiver burden (assessed via the ZBI) have been
reported in previous longitudinal studies (Brodaty
et al., 2014, in a general dementia population;
Conde-Sala et al., 2014; Jones et al., 2017), but
the current study is the first to provide confirmation
that wider, more objective aspects of the caregiver
burden—caregiver hours and informal care costs—
are also impacted by increases in patient functional
impairments over time. Hence, the early introduc-
tion of interventions aimed at slowing functional
Figure 2. Estimates of change from baseline (CFB) over 36 months (±95% confidence interval) for (A) caregiver burden (Zarit Burden Index
[ZBI] score); (B) caregiver basic activities of daily living (ADL) hours; (C) caregiver instrumental ADL hours; and (D) estimates of caregiver
informal care costs over 36 months. All mixed-effects models of repeated measures (MMRM) were controlled for country and baseline
scores and included patient and caregiver baseline covariates found to be significantly associated with each outcome of interest over 18
months; change in score from baseline to 18 months for four time-dependent patient covariates (Mini-Mental State Examination [MMSE],
Alzheimer’s Disease Cooperative Study—Activities of Daily Living [ADCS-ADL] [basic and instrumental], and Neuropsychiatric Inventory-12
[NPI-12]); and baseline scores for these time-dependent covariates.
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decline in patients with ADD may help reduce all
aspects of the caregiver burden (subjective and
objective). Various pharmacological and nonphar-
macological (e.g. exercise) interventions have dem-
onstrated efficacy in delaying functional decline in
individuals with dementia, including those with AD
(Laver et al., 2016).
We also found that behavioral decline impacted
subjective caregiver burden, as reported in previous
longitudinal and cross-sectional studies (Bergvall
et al., 2011; Brodaty et al., 2014; Conde-Sala
et al., 2014). A prospective, observational study
reported an improvement in behavioral disturbances
and a reduction in subjective caregiver burden
(assessed via the ZBI) in patients with ADD at 12
months (Agüera-Ortiz et al., 2010). However, dif-
ferences between the current study and this earlier
trial hinder comparisons. The earlier study was
Figure 2. Continued.
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conducted in patients with moderate-to-severe
ADD (MMSE score <20), a substantial proportion
of whom were in residential care. Additionally, the
study used the Blessed Dementia Scale, not the
NPI-12, to assess behavioral disturbances and found
that the use of pharmacotherapy and, in contrast to
the current study, patients having a higher level of
education, were associated with a lower caregiver
burden.
In a systematic review examining associations
between specific items on the NPI-12 and caregiver
burden in dementia (mainly AD), Terum et al.
(2017) found that irritability, followed by agitation,
sleep disturbances, anxiety, apathy, and delusion
seemed to have the greatest impact on caregiver
burden. While we did not explore which NPI-12
items were most relevant to the change in caregiver
burden over time, our study found that an increase
in NPI-12 total score was associated with greater
caregiver burden in ADD but not increased care-
giver time or informal care costs.
We found no evidence that a decline in cognition
over 18 months, having accounted for all other
variables in the models, including the decline in
function, was associated with changes in subjective
or objective measures of caregiver burden over
36 months. A recent report that a decline in
cognitive function (together with increasing fun-
ctional impairment and level of neuropsychiatric
symptoms) was associated with higher caregiver
burden in a longitudinal study in patients with
subjective cognitive decline or progressive neuro-
cognitive disorder followed for approximately 12
months suggests that reductions in patient cognition
may have more of an impact on caregiver burden in
the predementia phase (Dauphinot et al., 2016).
Although there has been an assumption that
increasing caregiver hours will impact informal
care costs (Wimo et al., 2013; Wolfs et al., 2012),
the current analysis in patients with ADD demon-
strated a direct association between functional
decline over 18 months (but not cognitive or behav-
ioral decline) and an increase in both informal
caregiver time and informal care costs over 36
months. The longitudinal Predictors Study, in
community-dwelling patients with mild AD, found
that increasing impairments in function were asso-
ciated with increased caregiver time and costs over a
four-year period but also reported no such associa-
tion with cognitive or behavioral problems (Zhu
et al., 2006; 2008).
Another key factor that the current study identi-
fied as associated with objective aspects of the long-
term caregiver burden was the caregiver living with
the patient at baseline. Unlike previous longitudinal
studies examining the factors associated with care-
giver burden over time (Conde-Sala et al., 2014;
Viñas-Diez et al., 2017), we found no association
Figure 3. Least squares (LS) mean change from baseline over 36 months (±95% confidence interval) in (A) caregiver basic ADL hours; (B)
caregiver instrumental ADL hours; and (C) LS mean caregiver informal care costs over 36 months.
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between the caregiver cohabiting with the patient at
baseline and greater subjective caregiver burden, as
assessed using the ZBI, at 36 months. However,
living with the patient at baseline was associated with
increases in objective measures, such as caregiver
basic and instrumental ADL hours and informal
care costs. These findings suggest that the proximity
of the caregiver to the patient, allowing him/her to be
readily available to assist with the patient’s care
needs, is a significant risk factor for a higher objec-
tive caregiver burden. Living with a patient with
ADD has been identified as a factor associated
with a greater caregiver burden (Kim et al., 2012;
Raccichini et al., 2015; Reed et al., 2014). Greater
increases in caregiver instrumental ADL hours and
informal care costs over 36 months were also
observed in caregivers (adult-child or spousal/part-
ner) who were not married at baseline.
This study was conducted in a large, well-
characterized, selected patient cohort from which
longitudinal data were collected prospectively over a
36-month period. However, as the study enrolled
approximately equal numbers of patients in eachAD
severity group (resulting in the inclusion of a larger
proportion of patients with moderately severe/severe
AD than would be typical of community-dwelling
AD patients), its findings may not be representative
of the full caregiver burden spectrum. The study
assessed the effect of cognitive, functional, and
behavioral decline on caregiver outcomes, all impor-
tant facets of AD progression and recommended
efficacy endpoints for clinical trials in AD (European
Medicines Agency, 2016). The use of a standardized
measure of resource use, including informal care,
facilitated the pooling of data from two countries;
however, the potential difficulties in interpreting
pooled data from different countries, with differing
health and social care systems, and varying ap-
proaches to the management of AD, should be
noted. This is reflected in the higher baseline levels
of caregiver time, the greater increases in caregiver
basic and instrumental ADL hours, the higher infor-
mal care costs, and lower increases in subjective
caregiver burden (ZBI score) over 36 months seen
in caregivers living in Germany than in those living
in France. These findings are consistent with those
of a previous GERAS report analyzing the factors
driving between-country differences in the costs of
AD, which found societal costs (driven largely by
informal care costs) over 18 months to be higher in
Germany than in France (Reed et al., 2017).
Only community-dwelling patients retained in
the study were followed-up at 36 months, leading
to possible bias frommissing data, a common occur-
rence in longitudinal studies in older adults where
patients may be lost to follow-up for reasons includ-
ing institutionalization and death (Coley et al., 2011;
Hardy et al., 2009). However, sensitivity analyses in
which missing ZBI scores were imputed using MI
found substantively similar results to the main anal-
yses, suggesting that the pattern of missing outcome
values had little impact on the results.
Although function was assessed during the study
less regularly than cognition or behavioral symptoms,
the associations between functional assessments and
all caregiver outcomes were strong, despite the level
of patients discontinuing from the study.
The analysis does not take into account the
influence of any health and social care resources
being provided to support patients and caregivers.
Additionally, other measures of caregiver impact
may be relevant but were not explored in this
study.
Conclusion
The study provides evidence that long-term (36-
month) informal caregiver burden is driven by wors-
ening functional abilities and behavioral symptoms,
but not cognitive decline, over 18 months in
community-dwelling patients with ADD. Care-
givers of patients with ADD therefore offer a unique
perspective on the impact of the disease, and their
inclusion is warranted during evaluations of pro-
grams and interventions aimed at reducing caregiver
burden. Prompt care planning for people with early-
stage ADD could help trigger targeted support for
caregivers, especially those living with an affected
person. Such initiatives, and effective treatment
options aimed at reducing patient functional impair-
ments and behavioral problems, could help mitigate
the impact of long-term informal caring for a patient
with ADD and need to be evaluated.
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